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INTRODUCTION
Upper gastrointestinal hemorrhage is the most common
complication of peptic ulcers. In approximately 20% of pa-
tients, ulcer-related hemorrhage occurs without preceding
symptoms (1). Bleeding persists or recurs in a subgroup of
these patients, which contributes to an overall mortality rate
of 6-10%. This rate has remained remarkably stable over the
past 20-30 yr (2), despite the tremendous advances in support-
ive care techniques such as blood-banking, intensive care units,
and endoscopy (3-9).
Gastric hemorrhage may occur for many reasons, such as
eroded vessels in an active ulcer, portal hypertension, or mul-
tiple gastric erosions. It has been assumed that this feature does
not occur in all peptic ulcer cases (10). Many independent risk
factors for ulcer hemorrhage have been described, such as high-
er age, use of nonsteroidal anti-inflammatory drugs (NSAIDs),
and a history of prior peptic ulcers (11, 12). However, there is
no satisfactory explanation of the pathogenesis of ulcer bleed-
ing: Helicobacter pylori (HP) has not been shown to be an inde-
pendent risk factor for ulcer hemorrhage (13), gastric acid hy-
persecretion is not necessary for hemorrhage in patients with
peptic ulcers, and no significant differences in secretory para-
meters (e.g., baseline, peak, or meal-stimulated acid outputs, and
parietal cell sensitivity) have been noted among ulcer patients
with and without bleeding (14). Therefore, further studies are
needed to determine the exact mechanism of ulcer hemorrhage.
Many reports have indicated that the fibrinolytic system
plays a significant role in gastric bleeding (15-18), but most
of these have focused on a specific parameter of the fibrinolyt-
ic system adjacent to the ulcer. The fibrinolysis, which is medi-
ated mainly by the tissue plasminogen activator (t-PA) and
plasminogen activator inhibitor type 1 (PAI-1), is a reparative
process that occurs in response to hemostatic plug or throm-
bus formation (19). The fibrin that is formed during hemosta-
sis must be removed when normal tissue structure and func-
tion is restored. Thus, a fibrin clot that forms quickly in a torn
blood vessel to stop hemorrhage is remodeled and then re-
moved to restore normal blood flow. The fibrinolytic system
is the principal effecter of clot removal and controls the enzy-
matic degradation of fibrin. Its action is coordinated through
the interaction of activators, zymogens, enzymes, and inhibitors
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Tissue Plasminogen Activator and Plasminogen Activator Inhibitor
Type 1 Gene Polymorphism in Patients with Gastric Ulcer 
Complicated with Bleeding
Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-
1) may be involved in the pathogenesis of peptic ulcers through suppression of fib-
rinolysis. This study was designed to investigate associations of t-PA and PAI-1 genes
with clinical features of the patients with bleeding gastric ulcers. Eighty-four patients
with peptic ulcers and 100 controls were studied between January 1998 and April
2000. We used polymerase chain reaction and endonuclease digestion to genotype
for 4G/5G polymorphism in the promoter region of the PAI-1 gene and the Alu-repeat
insertion/deletion (I/D) polymorphism in intron h of the t-PA gene. Various clinical fea-
tures, including lesion site, bleeding event, recurrence of ulcer, and rebleeding, were
assessed using a multiple logistic regression model. The genotype distributions of
both the t-PA and PAI-1 genes did not differ between the patient and control groups.
The occurrence of the I/D or D/D genotype of t-PA was significantly higher in cases
of duodenal ulcer (adjusted OR=4.39, 95% CI=1.12-17.21). When a dominant effect
(i.e., 4G/4G or 4G/5G versus 5G/5G) of the 4G allele was assumed, the PAI-1 4G/
4G genotype was independently associated with rebleeding after hemostasis (adjust-
ed OR=5.07, 95% CI=1.03-24.87). Our data suggest that t-PA gene polymorphism is
associated with duodenal ulcers, and that the PAI-1 gene may be a risk factor lead-
ing to recurrent bleeding after initial hemostasis.
Key Words : Tissue Plasminogen Activator; Plasminogen Activator Inhibitor 1; Peptic Ulcer; Fibrinolysis;
Hemostasis
Received : 4 September 2002
Accepted : 1 November 2002t-PA and PAI-1 Gene in Patients with Gastric Ulcer 59
to provide local activation at the site of fibrin deposition.
Various methods have been used to evaluate systemic fibri-
nolytic activity, such as monitoring the euglobulin fibrinolyt-
ic activity, chromogenic bioassay, enzyme-linked immunosor-
bent assay, and radioimmunoassay for t-PA and PAI-1. How-
ever, there are several reasons why these methods do not pro-
vide an accurate measure of the patient’ s physiologic fibrinolyt-
ic activity: (a) physiologic fibrinolysis does not occur in the
circulating blood but at the fibrin and/or thrombus site, so any
method that measures fibrinolytic activity in a sample of cir-
culating blood does not reflect fibrin-associated fibrinolysis;
(b) the release of t-PA from endothelial cells can be modified
by many factors such as exercise, venous occlusion, mental
stress, sympathetic stimulation, and prostaglandin (20); and
(c) variations in blood levels of PAI-1 are resulted from changes
in the rate of PAI-1 gene expression in the tissue rather than
from the release of stored PAI-1 in the cells (19). With these
factors kept in mind, it seems likely that the fibrinolytic activ-
ity measured at the gene level may provide a better assessment
of fibrinolysis.
There is recent evidence that 4G/5G polymorphism in the
promoter region of the PAI-1 gene is related to circulating
PAI-1 levels (21-24). In vitro experiments have shown that
both alleles of the 4G/5G polymorphism contain a binding
site for a transcription activator, and that the 5G allele also
contains a binding site for a transcription repressor that partial-
ly overlaps with the activator binding site (21, 25). Therefore,
the 4G allele of the PAI-1 gene is associated with increased
basal gene transcription. The 4G/4G genotype of PAI-1 has
been shown to be associated with ischemic heart disease (24,
26) and myocardial infarction (MI) (21, 27).
Similarly, the insertion/insertion (I/I) genotype of Alu-repeat
insertion/deletion (I/D) polymorphism in the t-PA gene has
been shown to be associated with the plasma PAI-1 antigen in
patients with MI (28). Since t-PA and PAI-1 levels are posi-
tively correlated, the Alu-repeat I/D polymorphism could be
a marker of a functional mutation in the t-PA gene that reg-
ulates the interaction between t-PA and PAI-1. The Alu-repeat
insertion may also be closely linked to a mutation at or near
the t-PA gene that produces a functional effect, and an Alu-
repeat I/D event can alter mRNA stability and splicing (29).
Although Alu-repeat I/D polymorphism in the t-PA gene is
not associated with either t-PA plasma levels (28) or the basal
synthesis rate of t-PA in endothelial cells (30), Alu-repeat I/D
polymorphism in the t-PA gene may be a candidate marker
for thrombosis and hemostasis (31).
The major pathogenic mechanisms for peptic ulcer are acid,
HP, and NSAIDs (1). Of these factors, only NSAIDs appear
to be an important risk factor for the development of bleed-
ing (32-34). In order to avoid any influence of this factor in our
study, we excluded any patient who had a history of NSAID
within 3 months of the study.
Intramucosal proteolysis has been considered to be an aggres-
sive factor in the development of peptic ulcers, and it has been
shown that there is a significantly higher level of protease activ-
ity at the ulcer edge and from the antral mucosa of patients
with an active duodenal ulcer (15-17). HP can induce peptic
ulceration through direct production of several proteases capa-
ble of damaging the gastroduodenal mucosa (34, 35). It is well
known that plasmin, the end product of the fibrinolytic sys-
tem, converts latent collagenase to an active form. The main-
tenance of an adequate mucosal blood flow by adequate fib-
rinolysis is another essential protective factor (28, 29), and t-
PA may be a key enzyme in this process. Nonetheless, the role
of the fibrinolytic system on the development of peptic ulcers
and/or ulcer bleeding is controversial.
Taking these observations into consideration, we hypoth-
esized that the t-PA and PAI-1 genes are factors leading to
peptic ulcer and hemorrhage. In order to determine whether
our hypothesis was correct, we analyzed I/D type polymor-
phism in intron h of the t-PA gene and 4G/5G polymorphism
in the promoter of the PAI-1 gene in patients with gastric ul-
cers with or without ulcer bleeding.
MATERIALS AND METHODS 
Study subjects
Between January 1998 and April 2000, diagnostic and/or
therapeutic endoscopy was performed in 84 patients with ac-
tive peptic ulcers. The control group comprised 100 subjects
who presented consecutively for multiphasic health check-up
at Soonchunhyang University Chunan Hospital. Individuals
with an NSAID-induced ulcer, underlying systemic disease,
or bleeding tendency were excluded from the study.
The study design was approved by the Ethics Committee
of Soonchunhyang University Chunan Hospital. Informed
consent was obtained from all subjects.
We used historical information and endoscopic examinations
to evaluate the lesion site for the presence of bleeding, recur-
rency, and HP infection. We performed several tests for HP
infection, including a rapid urease test (CLO test; Ballard, Dr-
aper, Australia) that was observed for up to 24 hr, histological
examination of an endoscopic biopsy, 13C-labeled urea breath
test (UBT), and serologic examination for the presence of imm-
unoglobulin G antibody to HP (Radim, Pomezia, Italy). We
determined the presence of HP infection in patients when two
or more of the above tests produced positive results. Rebleed-
ing was defined as the persistence or redevelopment of overt
bleeding (hematemesis, melena, or hematochezia) or a reduc-
tion in hemoglobin of more than 1.5 g/dL within 5 days of
initial hemostasis.
Blood sampling and DNA isolation
Blood samples were obtained from the antecubital vein be-
tween 7 a.m. and 9 a.m. after a fast and a 20 min rest. For DNA60 H.-S. Kim, K.-Y. Hwang, I.-K. Chung, et al.
analysis, blood was collected in K-EDTA vacuum tubes, and
stored at -70℃. DNA was isolated using a commercial ge-
nomic DNA purification kit (QIAamp; QIAGEN, Valencia,
CA, U.S.A.). Serum was separated from whole blood and used
for biochemical assays.
Determination of genotypes
Allele-specific polymerase chain reaction (PCR) was per-
formed according to Falk’ s assay (32) with some modifications.
The PAI-1 4G/5G polymorphism was determined for each
subject using two 17-mer allele-specific primers: 5′ -GTCT-
GGACACGTGGGGG-3′for insertion 5G allele and 5′ -G-
TCTGGACACGTGGGGA-3′for deletion 4G allele, in com-
bination with the common downstream primer 5′ -TGC-
AGCCAGCCACGACGTGATTGTCTA-3′ . The PCR ampli-
fied 140-bp DNA fragments with the 5G-specific primer only,
whereas in the 4G/4G genotype only 139-bp DNA fragments
with the 4G-specific primer, and in heterozygotes both 140-
and 139-bp DNA fragments were amplified. As a positive
control for the PCR, a 256-bp DNA fragment was generated
using a fourth primer, 5′ -AAGCTTTTACCATGGTAACC-
CCTGGT-3′ , located upstream of the polymorphic region in
combination with the downstream primer. Each DNA ampli-
fication was performed in a total volume of 25  L using 150-
200 ng of genomic DNA. The reaction mixture contained
50 mM Tris-HCl buffer (pH 9.0), 1.5 mM MgCl2, 0.2 mM
of each deoxyribonucleoside triphosphate, and 0.6  M of each
primer, except for the upstream control primers which were
0.12  M and 1.0 U of DNA polymerase. The mixture was
subjected to 35 155-sec-long cycles of 94℃ for 35 sec, 65℃
for 45 sec, and 72℃ for 75 sec. The PCR products were sep-
arated by 2% agarose gel electrophoresis, stained with ethid-
ium bromide, and viewed under UV light.
An I/D polymorphism resulting from the presence or absence
of an Alu repeat in intron h of the t-PA gene was identified in
all subjects. Briefly, 25-50 ng of each genomic DNA sample
was amplified by PCR in 25- L reaction volumes. Upstream
(5′ -TCCGTAACAGGACACCTCA-3′ ) and downstream (5′ -
ACCGTGGCTTCAGTCATGGA-3′ ) primers were chosen as
previously described (31). Briefly, 50 ng of DNA was ampli-
fied in a 25  L reaction containing 45 mM Tris-HCl (pH 8.0),
11 mM ammonium sulfate, 4.5 mM MgCl2, 6.7 mM 2-mer-
captoethanol, 4.4  M K-EDTA (pH 8.0), 1 mM each of dNTP,
100  g/mL bovine serum albumin, 0.01% gelatin, 10 pmol
of each primer, and 1 unit of Taq polymerase. The reaction
was initially heated to 94℃ for 5 min, which was followed
by 30 3-min-long cycles of 94℃for 1 min, 58℃for 1 min,
and 72℃ for 1 min. Amplified products (I allele=967 base
pairs, D allele=655 base pairs) were resolved on 1.5% agarose
gels and visualized by ethidium bromide fluorescence. Samples
were classified according to three genotypes: I/I, D/D, and I/D.
The classification was determined independently by two indi-
viduals who had no knowledge of the case or control status.
The PCR direct sequencing was carried out from randomly
selected samples to confirm the accuracy of allele-specific
oligonucleotide genotyping.
Statistical analysis
Differences in baseline characteristics among three groups
were evaluated by analysis of variance (ANOVA) and  2 tests
for continuous and categorized variables, respectively. The ob-
served numbers of each PAI-1 genotype and each t-PA geno-
type were compared with those expected for a population in
Hardy-Weinberg equilibrium using a  2 test. Associations of
PAI-1 and t-PA genotypes with the presence of peptic ulcers
were estimated using odds ratio (OR) and 95% confidence
interval (CI) measures. Both dominant and recessive models
were constructed to test the associations. Multiple logistic
regression was applied to evaluate the independent associa-
tion of the PAI-1 4G/5G polymorphism and t-PA I/D poly-
morphism with peptic ulcer, whilst controlling for possible
confounding factors. Gene-gene interaction between PAI-1
and t-PA on peptic ulcer parameters was also assessed. Sta-
tistical analysis was performed using SPSS for Windows V
10.0 (SPSS Inc., Chicago, U.S.A.). Pvalues less than 0.05 were
considered to be statistically significant. 
RESULTS
Profile of patients
The clinical profiles of the patients are given in Table 1.
Genotypes for PAI-1 and t-PA were available in 84 patients
with peptic ulcer and 100 and 98 of the controls, respective-
ly. The mean (SD) age of the patients was 58.6 yr (15.1 yr),
and 67 (79.8%) of them were male. The peptic ulcer was gas-
tric in 56 cases and duodenal in 28 cases; its phase was cate-
gorized as initial in 64 cases and recurrent in 20 cases. Clin-
ical bleeding was observed in 56 cases (66.7%). Of 32 patients
subjected to the CLO test, 84.4% were positive. Fifty-six (66.7
%) of the patients regularly drank alcohol, and 59 (70.2%)
were cigarette smokers.
The clinical outcomes are presented in Table 2. Sixty patients
required blood transfusion and 4 patients needed surgical oper-
ation for hemostasis. Rebleeding was observed in 9 patients.
The mean (SD) duration of hospital treatment was 14.1 (8.8)
days.
Gene polymorphisms of t-PA and PAI-1
The distribution of t-PA genotypes in 84 patients with a
peptic ulcer was: 32 (38.1%) D/D, 30 (35.7%) I/D, and 22
(26.2%) I/I. This distribution was not significantly different
from that of 98 control subjects (p=0.180): 25 (25.5%) D/D,
40 (40.8%) I/D, and 33 (33.7%) I/I (Table 3). No significantt-PA and PAI-1 Gene in Patients with Gastric Ulcer 61
difference in frequency of the I allele was observed between
control subjects (0.54) and peptic ulcer patients (0.63) (p=
0.193).
The distribution of PAI-1 genotypes in the patients was: 26
(31.0%) 4G/4G, 42 (50.0%) 4G/5G, and 16 (19.1%) 5G/5G.
This distribution was not significantly different from that of
the 100 control subjects: 21 (21.0%) 4G/4G, 53 (53.0%) 4G/
5G, and 26 (26.0%) 5G/5G (p=0.245, Table 3).
Relations of gene polymorphism with ulcer site and
rebleeding
Using a multiple logistic regression model in which a reces-
sive effect (I/I vs. I/D or D/D) of the I allele was assumed, the
I/I genotype of t-PA was found to be related to the presence of
peptic ulcers. The occurrence of the I/D or D/D genotypes of
t-PA was significantly higher in duodenal ulcers (adjusted
OR=4.39, p=0.034). However, PAI-1 was not related to ulcer
site in both dominant and recessive models (Table 4).
When a dominant effect (4G/4G or 4G/5G versus 5G/5G)
of the 4G allele was assumed, the PAI-1 4G/4G genotype was
*CLO test was performed in 32 patients.
Clinical variables n (%)
Age (yr), mean±SD 58.6±15.1
Gender
Male 67 (79.8)
Female 17 (20.2)
Lesion site
Duodenum 28 (33.3)
Stomach 56 (66.7)
Ulcer bleeding phase
Initial 64 (76.2)
Recurrent 20 (23.8)
Current bleeding
No 28 (33.3)
Yes 56 (66.7)
Past ulcer history
No 38 (45.2)
Yes 46 (54.8)
CLO test*
Negative 5 (15.6)
Positive 27 (84.4)
Regular alcohol drinker
No 28 (33.3)
Yes 56 (66.7)
Current smoker
No 25 (29.8)
Yes 59 (70.2)
Systemic disease
No 52 (61.9)
Yes 32 (38.1)
Table 1. Clinical profiles of 84 patients with active peptic ulcer
Clinical variables n (%)
Blood transfusion
No 24 (28.6)
Yes 60 (71.4)
Treatment
Endoscopy 80 (95.3)
Surgery 4 ( 4.7)
Rebleeding
No 75 (89.3)
Yes 9 (10.7)
Hospitalization duration (days), mean (SD) 14.1 (8.8)
Table 2. Therapeutic and prognostic profiles of 84 patients with
active peptic ulcer
Gene
Adjusted
OR*
Model 95% CI p value
t-PA Dominant
no vs rebleeding 1.83 0.41-8.25 0.429
Recessive
no vs rebleeding 3.95 0.40-38.66 0.237
PAI-1 Dominant
no vs rebleeding 5.07 1.03-24.87 0.045
Recessive
no vs rebleeding 0.97 0.20-4.58 0.966
Table 5. Associations between gene polymorphisms and
rebleeding
Genetic 
polymorphisms
Patients
n (%)
Controls
n (%)
p-value
t-PA 0.180
II 22 (26.2) 33 (33.7)
ID 30 (35.7) 40 (40.8)
DD 32 (38.1) 25 (25.5)
PAI-1 0.245
4G/4G 26 (31.1) 21 (21.0)
4G/5G 42 (50.0) 53 (53.0)
5G/5G 16 (19.1) 26 (26.0)
Table 3. Distributions of genetic polymorphisms of t-PA and
PAI-1 in patients and controls
*adjusted for age, gender, bleeding during endoscopy, ulcer site, alco-
hol consumption, and smoking.
Gene
Adjusted
OR*
Model 95% CI p value
t-PA Dominant
stomach vs duodenum 2.05 0.75-5.56 0.161
Recessive
stomach vs duodenum 4.39 1.12-17.21 0.034
PAI-1 Dominant
stomach vs duodenum 0.85 0.24-2.97 0.799
Recessive
stomach vs duodenum 1.16 0.41-3.26 0.783
Table 4. Associations between gene polymorphisms and site of
ulcer
*adjusted for age, gender, alcohol consumption, and smoking.62 H.-S. Kim, K.-Y. Hwang, I.-K. Chung, et al.
significantly and independently related to rebleeding after ini-
tial hemostasis (adjusted OR=5.07, p=0.045). However, nei-
ther the recessive model of PAI-1 nor recessive or dominant
model of t-PA was related to rebleeding (Table 5).
The interactions between PAI-1 and t-PA were calculated
in both dominant and recessive models and evaluated for gene-
gene interaction on ulcer sites and rebleeding as well as other
clinical parameters in a further analysis. However, no signif-
icant interactions were observed (data not shown). 
DISCUSSION
In the present study, the occurrence of the I/D or D/D geno-
types of t-PA was higher in duodenal ulcers, and the PAI-1
4G/4G genotype was associated with rebleeding of a peptic
ulcer. These results suggest that the t-PA and PAI-1 system
plays a role in both ulcer formation and ulcer bleeding.
In our study, when age, gender, alcohol consumption, and
smoking habits were controlled, there was an association be-
tween the I/D or D/D genotype of t-PA and the presence of
a duodenal ulcer. This result suggests that the t-PA gene is
an independent factor in the pathogenesis of duodenal ulcers.
The so-called peptic ulcer disease encompasses both gastric
and duodenal ulcers (1). Duodenal and gastric ulcers share
many common features in terms of pathogenesis, diagnosis,
and treatment, but several factors distinguish the two. Gastric
ulcers tend to occur later in life than duodenal lesions. More
than half of gastric ulcers occur in males, and they are less com-
mon than duodenal ulcers. As for duodenal ulcers, the major-
ity of gastric ulcers can be attributed to either HP-or NSAID-
induced mucosal damage. Gastric ulcers that occur in the
prepyloric area or those associated with a duodenal ulcer are
similar to duodenal ulcers in terms of pathogenesis (1). The
exact mechanism of the formation of a peptic ulcer is beyond
the scope of this study. However, our results have shown that
the effects of the t-PA gene on peptic ulcer formation depends
upon whether the ulcer occurs in the stomach or in the duo-
denum.
The other question relating to our results is the significance
of the I/D and D/D genotypes of t-PA. Alu-repeat I/D poly-
morphism in the t-PA gene was not associated with either t-
PA plasma levels (28) or the basal synthesis rate of t-PA in en-
dothelial cells (30). Therefore, it is hard to explain why stim-
ulated fibrinolysis is implicated in the pathogenesis of a duo-
denal ulcer. However, the I/I genotype of Alu-repeat I/D poly-
morphism in the t-PA gene shows an association with plasma
PAI-1 antigen in patients with MI (28). Since t-PA and PAI-
1 levels are positively correlated, the Alu-repeat I/D polymor-
phism could be a marker of a functional mutation in the t-PA
gene that regulates the interaction between t-PA and PAI-1.
In this regard, Alu-repeat I/D polymorphism in the t-PA gene
may be a candidate marker for thrombosis and hemostasis (31).
Further studies are needed to clarify the property of the I/D
or D/D genotypes of t-PA during duodenal ulcer formation.
Contrary to our expectations, the PAI-1 4G/4G genotype
was an independent risk factor for rebleeding. It is known that
an increased PAI-1 concentration induces decreased plasmin
formation and leads to an accumulation of fibrin. The 4G allele
and the 4G/4G genotype of PAI-1 have been reported to be
associated with increased basal gene transcription, and conse-
quently have been regarded as thrombogenic factors (21, 24,
26, 27). With this kept in mind, our results are suggestive of
some other role of PAI-1 in the process of rebleeding, except
the effect on fibrinolytic activity.
PAI-1 is synthesized by endothelial cells and hepatocytes,
and is present mainly in platelets and plasma. But some PAI-
1 is also present in the subendothelial extracellular matrix,
where its function may be inhibition of local proteolysis. PAI-
1 activity induces changes in remodeling of the vessel wall
through activation of metalloproteinases, growth factors, and
degradation of the extracellular matrix (26, 27). In addition
to its antiprotease activity, PAI-1 participates in the cellular
adhesion and migration processes (36). Taken the well-known
function of PAI-1 to inhibit local proteolysis into consideration,
our results suggest that disturbed vessel wall remodeling may
be involved in the rebleeding of peptic ulcers.
In the normal physiological state, the activities of coagula-
tion and fibrinolysis are balanced. However, increased activity
of either coagulation or fibrinolysis can overwhelm the other,
to the extent of producing a clinical problem. Therefore, in-
creased fibrinolysis and/or decreased coagulation may be in-
volved in the pathogenesis of ulcer hemorrhage. However, we
believe that the role of t-PA and PAI-1 in peptic ulcer bleed-
ing differs between current-bleeding and rebleeding situations.
Furthermore, it seems likely that peptic ulcer rebleeding is
due in large part to the properties of PAI-1, which disturbs
remodeling of injured vessel after initial bleeding.
In conclusion, our data suggest that t-PA gene polymor-
phism may be associated with duodenal ulcers, and that the
PAI-1 gene may be a risk factor leading to recurrent bleeding
after initial hemostasis.
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